daclizumab   Click here for help

GtoPdb Ligand ID: 6880

Synonyms: L04AC01 | RO-24-7375 | Ro-247375 | Zenapax®
Approved drug Immunopharmacology Ligand
daclizumab is an approved drug (FDA FDA (1997), EMA (1999))
Compound class: Antibody
Comment: Daclizumab is a monoclonal antibody binding to the α subunit (CD25) of the high-affinity interleukin-2 receptor.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

An advanced version of daclizumab, with identical primary sequence, but which is differentially gylcosylated, called daclizumab beta (BIIB019, DAC HYP) has been developed for subcutaneous administration. Daclizumab beta's alternate glycosylation pattern changes its binding to Fc receptors and reduces its propensity to induce complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC).
Click here for help
Bioactivity Comments
Peptide sequence analysis of the heavy chain variable region of daclizumab provides a match with patented sequence from US5693761 [2].
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
Interleukin-2 receptor subunit α Primary target of this compound Hs Antibody Binding >8.0 pKd - 2
pKd >8.0 (Kd <1x10-8 M) [2]